Zevra Therapeutics, Inc. - Common Stock (ZVRA)

Zevra (ZVRA) Q3 2025 Earnings Call Transcript

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

Zevra Therapeutics (NASDAQ: ZVRA) has captured significant attention in the financial markets with its recent robust stock performance and a compelling "Strong" Relative Strength Rating. As of early October 2025, the biopharmaceutical company, focused on rare diseases, is demonstrating a positive trajectory, fueled by critical regulatory milestones, impressive financial results,

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy rating on rare disease strength.

Zevra Therapeutics shares are trading higher by 6.7% Wednesday morning. The company reported better-than-expected Q1 financial results.

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.